Positive Cohort B ASCEND data: 6M PFS 60.8% (certepetide) vs 25% (placebo)

LISATA THERAPEUTICS, INC.

Cohort B: median PFS 7.5 months (certepetide) vs 4.7 months (placebo); ORR 45.2% vs 19%.
Median OS 10.32 months (certepetide) vs 9.23 months (placebo); safety profile attractive.
Cohort B regimen (two doses of certepetide) showed clinically meaningful improvement over Cohort A.
Full data from both cohorts expected later 2025; presented at ESMO GI on 2 July 2025.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.